IN8bio (INAB) to Post Quarterly Earnings on Thursday

IN8bio (NASDAQ:INAB) is expected to be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.3437) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

IN8bio (NASDAQ:INAB) last posted its earnings results on Thursday, May 7th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.33. On average, analysts expect IN8bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

IN8bio Stock Performance

Shares of INAB traded down $0.00 during trading hours on Tuesday, hitting $0.96. The stock had a trading volume of 8,135 shares, compared to its average volume of 65,847. The firm has a 50-day moving average price of $1.40 and a 200 day moving average price of $1.61. IN8bio has a fifty-two week low of $0.94 and a fifty-two week high of $2.73. The firm has a market capitalization of $9.45 million, a price-to-earnings ratio of -0.37 and a beta of 0.24.

Analyst Upgrades and Downgrades

INAB has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of IN8bio in a report on Thursday, June 4th. Weiss Ratings restated a “sell (e+)” rating on shares of IN8bio in a research report on Friday, July 17th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $4.00.

Institutional Investors Weigh In On IN8bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. HRT Financial LP acquired a new position in shares of IN8bio during the 4th quarter worth about $34,000. Captrust Financial Advisors acquired a new stake in IN8bio in the 4th quarter worth about $43,000. Citadel Advisors LLC purchased a new stake in IN8bio during the 3rd quarter worth approximately $54,000. Two Sigma Investments LP purchased a new stake in IN8bio during the 3rd quarter worth approximately $107,000. Finally, Franklin Resources Inc. raised its holdings in shares of IN8bio by 381.6% during the fourth quarter. Franklin Resources Inc. now owns 914,531 shares of the company’s stock valued at $2,048,000 after acquiring an additional 724,637 shares during the last quarter. Hedge funds and other institutional investors own 92.05% of the company’s stock.

IN8bio Company Profile

IN8bio is a clinical-stage biopharmaceutical company developing ?? T cell therapeutic and ?? T cell engager (TCE) product candidates to address unmet medical needs. ?? T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic ?? T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.